Novartis' Cosentyx Receives US FDA Approval for Polymyalgia Rheumatica
Novartis receives US FDA approval for Cosentyx 150 mg to treat adults with polymyalgia rheumatica, making it the first anti-IL-17 biologic approved for the condition.
Corticosteroid Tapering | 18/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy